A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD

Conditions

• Chronic Obstructive Pulmonary Disease

Interventions

• DRUG: Glycopyrrolate (85 μg)
• DRUG: Glycopyrrolate (42.5 μg)
• DRUG: Glycopyrrolate (14 μg)
• DRUG: Placebo

Sponsor

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA